RxDoctor Payments Data

Brian Mitchell, MD

Neurology · Athens, GANPI 1548212475

Payments from drug & device makers

$5,225in general payments, 2019–2025

Across 349 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$312
  • Novartis$294
  • Pfizer$250
  • Teva Pharmaceuticals USA, Inc.$239
  • Amgen$222
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$5,206100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,225 in reported general payments places this provider in the 60th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$698,906
Medicare patients
969
Services billed
74,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate20$114,965
CopaxoneGlatiramer Acetate15$86,077
Emgality PenGalcanezumab-Gnlm87$65,490
MigergotErgotamine Tartrate/Caffeine12$62,627
Ajovy AutoinjectorFremanezumab-Vfrm41$33,975
Nurtec OdtRimegepant Sulfate24$26,946
GlatopaGlatiramer Acetate11$21,450
Aimovig AutoinjectorErenumab-Aooe24$18,633
TopamaxTopiramate13$14,011
DepakoteDivalproex Sodium13$8,350
RytaryCarbidopa/Levodopa14$8,034
Ajovy SyringeFremanezumab-Vfrm11$7,933
Topiramate100$7,149
Carbidopa-LevodopaCarbidopa/Levodopa260$6,712
Carbamazepine ErCarbamazepine26$6,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$96$114,96520 claims
Teva Pharmaceuticals USA, Inc.Copaxone$239$86,07715 claims
AmgenMigergot$222$62,62712 claims
PfizerNurtec Odt$250$26,94624 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$48$15,002109 claims
Upsher-smith Laboratories LLCTopiramate$16$7,149100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 506 neurology providers in Georgia.

Other neurology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →